Online citations, reference lists, and bibliographies.
← Back to Search

PLGA:poloxamer Blend Micro- And Nanoparticles As Controlled Release Systems For Synthetic Proangiogenic Factors.

Yolanda Parajó, I. d'Angelo, A. Horváth, T. Vántus, Kéri György, A. Welle, M. Garcia-Fuentes, M. Alonso
Published 2010 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Tissue engineering is one of the most promising research areas in bioregenerative medicine. However, the restoration of biological functionalities by implanting bioartificially engineered tissues is still highly limited because of their lack of vascular networks. The use of proangiogenic molecules delivered from a controlled release device is a promising strategy to induce tissue vascularization. Indeed, the controlled release system can enhance the therapeutic effect in vivo of many short half-life drugs, while circumventing the need for repeated administrations. In this work, PLGA:poloxamer blend based micro- and nanoparticles have been developed for the sustained delivery of a recently developed synthetic proangiogenic compound: SHA-2-22. Drug-loaded PLGA:poloxamer blend microparticles were prepared by an oil-in-oil solvent extraction/evaporation technique. Drug-loaded PLGA:poloxamer nanoparticles were prepared by a modified solvent diffusion technique. These drug carriers were characterized with regard to their physicochemical properties, morphology, drug encapsulation efficiency and release kinetics in vitro. The results show that by adjusting the formulation conditions, it is possible to obtain PLGA:poloxamer micro- and nanoparticles with very high drug loadings, and with the capacity to release the active compound in a controlled way for up to one month. In vitro cell assays performed in an endothelial cell model confirmed the bioactivity of SHA-22-2 encapsulated in PLGA:poloxamer microparticles.
This paper references
10.1016/J.JCONREL.2007.09.013
Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
R. C. Mundargi (2008)
10.1016/S0168-3659(01)00430-8
Non-aqueous encapsulation of excipient-stabilized spray-freeze dried BSA into poly(lactide-co-glycolide) microspheres results in release of native protein.
K. G. Carrasquillo (2001)
10.1016/j.ijpharm.2008.04.042
Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles.
C. Wischke (2008)
10.1007/PL00007070
Systems for therapeutic angiogenesis in tissue engineering
S. Soker (2000)
10.1007/S00396-009-2131-Z
Protein-loaded PLGA–PEO blend nanoparticles: encapsulation, release and degradation characteristics
M. J. Santander-Ortega (2010)
10.1166/JBN.2009.022
Insulin-loaded PLGA nanoparticles for oral administration: an in vitro physico-chemical characterization.
M. J. Santander-Ortega (2009)
10.1016/J.JCIS.2006.07.031
Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms.
M. J. Santander-Ortega (2006)
10.1016/J.JBIOTEC.2005.03.016
VEGF profiling and angiogenesis in human microtissues.
J. Kelm (2005)
10.1023/A:1007502828372
Growth Factor Delivery for Tissue Engineering
J. Babensee (2004)
Effect of New Synthetic Peptides and Peptidomimetics on Angiogenesis
A. Horváth (2007)
10.1016/J.BIOMATERIALS.2007.11.004
Nanosphere-mediated delivery of vascular endothelial growth factor gene for therapeutic angiogenesis in mouse ischemic limbs
Sun-Woong Kang (2008)
10.1163/1568562041753098
Design and characterisation of new nanoparticulate polymer blends for drug delivery
N. Csaba (2004)
10.1016/J.IJPHARM.2007.01.043
Stabilization of recombinant human growth hormone against emulsification-induced aggregation by Pluronic surfactants during microencapsulation.
Gang Wei (2007)
10.1002/jbm.a.32332
Bioactivation of collagen matrices through sustained VEGF release from PLGA microspheres.
C. Borselli (2010)
10.1016/S0378-5173(99)00178-7
Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres.
A. Sánchez (1999)
10.1038/nbt1101-1029
Polymeric system for dual growth factor delivery
T. P. Richardson (2001)
10.1016/S0928-0987(03)00019-8
Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha.
A. Sánchez (2003)
10.1016/J.CARDIORES.2004.11.020
Update on therapeutic neovascularization.
Y. Cao (2005)
10.1016/S0939-6411(98)00011-3
Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants.
D. Blanco (1998)
10.1023/A:1018820507379
A Novel System Based on a Poloxamer/ PLGA Blend as a Tetanus Toxoid Delivery Vehicle
M. Tobío (2004)
10.1016/S0098-2997(02)00008-0
Principals of neovascularization for tissue engineering.
M. Nomi (2002)
10.1016/J.JCONREL.2006.03.017
PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery.
N. Csaba (2006)
10.1016/J.EJPB.2004.10.006
Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles.
U. Bilati (2005)
10.1016/J.IJPHARM.2006.08.027
Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro.
H. Zhang (2007)
10.1002/jps.22149
Biocompatibility of an injectable in situ forming depot for peptide delivery.
Karin Schoenhammer (2010)
10.3109/02652040902954729
Improved delivery of angiogenesis inhibitors from PLGA:poloxamer blend micro- and nanoparticles
I. D'angelo (2010)
10.1002/adma.200900241
Controlled growth factor delivery for tissue engineering.
Prakriti Tayalia (2009)
10.1021/BM049577P
PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: new carriers for gene delivery.
N. Csaba (2005)
10.1016/J.COPBIO.2003.08.004
Protein-based signaling systems in tissue engineering.
T. Boontheekul (2003)
10.1016/S0736-0266(01)00054-7
Controlled‐release of IGF‐I and TGF‐β1 in a photopolymerizing hydrogel for cartilage tissue engineering
J. Elisseeff (2001)



This paper is referenced by
Développement d’une protéine à libération prolongée, mise au point du procédé d’encapsulation sans solvant halogéné et optimisation du profil de libération.
Fabien Violet (2015)
10.1016/j.msec.2015.09.018
Development of a novel starch with a three-dimensional ordered macroporous structure for improving the dissolution rate of felodipine.
Yanna Hao (2016)
10.1016/j.biomaterials.2013.12.001
Implantable controlled release devices for BMP-7 delivery and suppression of glioblastoma initiating cells.
Elaine Reguera-Nuñez (2014)
10.1021/bm300826v
Thermosensitive nanoparticles with pH-triggered degradation and release of anti-inflammatory cell-penetrating peptides.
Rush L. Bartlett (2012)
10.1080/02652048.2016.1208296
Preparation, statistical optimisation and in vitro characterisation of poly (3-hydroxybutyrate-co-3-hydroxyvalerate)/poly (lactic-co-glycolic acid) blend nanoparticles for prolonged delivery of teriparatide
Nika Bahari Javan (2016)
10.1016/j.heliyon.2019.e02289
Cyclic β-(1, 2)-glucan blended poly DL lactic co glycolic acid (PLGA 10:90) nanoparticles for drug delivery
Geetha Venkatachalam (2019)
Rational design and synthesis of drug delivery platforms for treating diseases associated with intestinal inflammation
D. S. Wilson (2011)
10.1109/TNANO.2012.2183004
PLGA Micro- and Nanoparticles Loaded Into Gelatin Scaffold for Controlled Drug Release
W. Asghar (2012)
10.5772/31264
Preparation and Characterization of Polymeric Microparticles Used for Controlled Release of Ametryn Herbicide
Fabiana Aparecida Lobo (2012)
UNIVERSIDADE FEDERAL DO RIO GRANDE DO NORTE CENTRO DE CIÊNCIAS DA SAÚDE PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS FARMACÊUTICAS MICROPARTÍCULAS DE POLI (ÁCIDO LÁCTICO)/POLOXÂMERO OBTIDAS POR SPRAY DRYING PARA LIBERAÇÃO MODIFICADA DE METOTREXATO
Edilene Gadelha de Oliveira (2013)
10.2147/IJN.S67947
Novel PLGA-based nanoparticles for the oral delivery of insulin
S. Malathi (2015)
10.1021/bm401141u
Development of PLGA-mannosamine nanoparticles as oral protein carriers.
Maria Alonso-Sande (2013)
10.1080/02652048.2016.1208296
Preparation, statistical optimisation and in vitro characterisation of poly (3-hydroxybutyrate-co-3-hydroxyvalerate)/poly (lactic-co-glycolic acid) blend nanoparticles for prolonged delivery of teriparatide
Nika Bahari Javan (2016)
10.1515/ntrev-2012-0051
Why is the nanoscale special (or not)? Fundamental properties and how it relates to the design of nano-enabled drug delivery systems
Daniel P Otto (2013)
10.1109/TNANO.2013.2279532
Salt-Leaching Synthesis of Porous PLGA Nanoparticles
A. Ilyas (2013)
10.1080/10286020.2017.1337751
Continuous synthesis and anti-myocardial injury of tanshinone IIA derivatives
Yin-lin Qin (2018)
10.1016/J.JDDST.2017.06.018
Advances on the formulation of proteins using nanotechnologies
Irene Santalices (2017)
10.4155/tde.12.144
Nanomedicine for uterine leiomyoma therapy.
Hazem Ali (2013)
10.1007/978-3-319-23183-9_7
Microbial Production of Polyhydroxyalkanoates for Agricultural and Aquacultural Applications
K. Shantini (2015)
10.3109/03639045.2013.767826
Design of polymeric nanoparticles and its applications as drug delivery systems for acne treatment
C. Reis (2014)
10.1016/j.ijpharm.2013.07.010
Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model.
Hazem Ali (2013)
10.1016/j.ejps.2017.02.018
Preparation, characterization and in vivo evaluation of a combination delivery system based on hyaluronic acid/jeffamine hydrogel loaded with PHBV/PLGA blend nanoparticles for prolonged delivery of Teriparatide
N. B. Javan (2017)
10.1111/1750-3841.12406
Preparation and characterization of carvacrol loaded polyhydroxybutyrate nanoparticles by nanoprecipitation and dialysis methods.
F. Shakeri (2014)
Semantic Scholar Logo Some data provided by SemanticScholar